Skip to main content

Clinical Cellular Therapy Research Laboratory (LTCC)

Description

The Institut Bordet Clinical Cellular Therapy Research Laboratory (LTCC) is dedicated to fundamental and translational research in the fields of haematology and immunology cellular therapy.

The LTCC’s main objectives concern:

  • study of the interaction between leukaemic cells and their microenvironment;
  • establishment of new prognostic factors;
  • development of new therapeutic strategies.

Within the field of cellular therapy, the LTCC is studying the functional characterisation of mesenchymal stromal cells obtained from different tissues and their manipulation with a view to increasing their therapeutic potential.

Research projects

Project 1

IMPACT OF CHRONIC LYMPHOCYTIC LEUKEMIA-DERIVED EXTRACELLULAR VESICLES ON THE MICROENVIRONMENT IMMUNE LANDSCAPE / IMPACT DES VÉSICULES EXTRACELLULAIRES DÉRIVÉES DE LEUCÉMIE LYMPHOÏDE CHRONIQUE SUR LES CELLULES IMMUNITAIRES DU MICROENVIRONNEMENT

Project 2

Phenotypical Characterization and functional Impact of extracellular vesicles from mesenchymal stromal cells on Chronic Lymphocytic Leukemia B-cells

Project 3

Extracellular vesicles derived from umbilical cord-mesenchymal stromal cells for targeted therapy in pancreatic cancer

Project 4

Immunosuppressive microenvironment in multiple myeloma: role of bone marrow-mesenchymal cell (BM-MSC) glycosylation

Project 5

The use of Adipose Tissue derived Stromal Vascular Fraction in a Platelet-Rich Fibrin scaffold within Medication-Related Osteonecrosis of the Jaw treatment
  • Project leader : Cyril Bouland  
  • Collaboration : Nathalie Meuleman, Isabelle Loeb
  • Funding : Fondation Vésal

Our team

Laboratory head
Laurence Lagneaux, PhD

The team
Basile Stamatopoulos, PhD
Karlien Pieters, laboratory technician
Florian Draguet, PhD student Télévie
Nathan Dubois, PhD student Télévie
Cyril Bouland, MD, PhD student
Florent Corrillon, scientific collaborator

 Scientific publications

Transcriptional Profile of Cytokines, Regulatory Mediators and TLR in Mesenchymal Stromal Cells after Inflammatory Signaling and Cell-Passaging.

Authors : Merimi M, Buyl K, Daassi D, Rodrigues RM, Melki R, Lewalle P, Vanhaecke T, Fahmi H, Rogiers V, Lagneaux L, De Kock J, Najar M
Year : 2021
Journal : Int J Mol Sci
Volume : 22

The Therapeutic Potential of Mesenchymal Stromal Cells for Regenerative Medicine: Current Knowledge and Future Understandings.

Authors : Merimi M, El-Majzoub R, Lagneaux L, Moussa Agha D, Bouhtit F, Meuleman N, Fahmi H, Lewalle P, Fayyad-Kazan M, Najar M
Year : 2021
Journal : Front Cell Dev Biol
Volume : 9
Pages : 661532

In Vitro Cellular and Molecular Interplay between Human Foreskin-Derived Mesenchymal Stromal/Stem Cells and the Th17 Cell Pathway.

Authors : Najar M, Merimi M, Faour WH, Lombard CA, Moussa Agha D, Ouhaddi Y, Sokal EM, Lagneaux L, Fahmi H
Year : 2021
Journal : Pharmaceutics
Volume : 13

Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF.

Authors : Bouland C, Meuleman N, Widelec J, Keiani-Mothlagh K, Voisin C, Lagneaux L, Philippart P
Year : 2021
Journal : J Stomatol Oral Maxillofac Surg
Volume : 122
Pages : 212-218

Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization.

Authors : Najar M, Melki R, Khalife F, Lagneaux L, Bouhtit F, Moussa Agha D, Fahmi H, Lewalle P, Fayyad-Kazan M, Merimi M
Year : 2021
Journal : Front Cell Dev Biol
Volume : 9
Pages : 716853